FDA indications of inhaled NO is: (A) Malignant hypeension, (B) Pulmonary hypeension in newborn, (C) Cyanotic CHD, (D) None of the above
Answer is B. "Inhaled nitric oxide has been approved by FDA for use in newborns with persistent pulmonary hypeension and has become the first line therapy for this disease. In this disease state, NO inhalation has been shown to reduce, significantly, the necessity for extracorporeal oxygenation".(Refer: Morgan and Mikhail's Clinical Anaesthesiology, 5th edition, pg no. 257)